Intellia Therapeutics to Present at November Healthcare Investor Conferences
03 November 2017 - 7:30AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on the development of curative therapeutics using
CRISPR/Cas9 technology, will present at the following upcoming
healthcare conferences in November:
Tuesday, November 7, 2017Credit Suisse
26th Annual Healthcare ConferenceWho: Tom Barnes, Ph.D.,
Senior Vice President, Innovation SciencesLocation: Scottsdale,
ArizonaPresentation Time: 9:45am MST (11:45am EST)
Wednesday, November 15, 2017Jefferies
London Healthcare ConferenceWho: John Leonard, M.D.,
Executive Vice President, R&DLocation: London, United
KingdomPresentation Time: 8:40am GMT (2:40am EST)
Thursday, November 30, 2017Barclays
Gene Editing/Therapy SummitWho: Nessan Bermingham, Ph.D.,
Chief Executive Officer and FounderLocation: New York, New York
Presentation Time: 1:40pm EST
A live webcast of Intellia’s presentations will be accessible
through the Events and Presentations page of the Investor Relations
section of the company’s website at www.intelliatx.com. To access
the webcasts, please log on to the Intellia website approximately
15 minutes prior to the start time to ensure adequate time for any
software downloads that may be required. A replay of the webcast
will be available on Intellia’s website for 14 days following each
conference.
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company focused on the
development of proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course. The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us
on Twitter @intelliatweets
Investor Contact:
Lindsey Trickett
Vice President, Investor Relations+1
857-285-6211
lindsey.trickett@intelliatx.com
Media Contact:Jennifer Mound SmoterSenior Vice
President, External Affairs &Communications1
857-706-1071jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024